Celgene announces purchase of Juno Therapeutics for USD 9 billion
Date: 2018-01-23   Author: Dhananjay Punekar  Category: #industry

Celgene announces purchase of Juno Therapeutics for USD 9 billion

In what may be regarded as a significant breakthrough being witnessed across healthcare industry, Celgene Corporation has reportedly decided to purchase Juno Therapeutics Incorporation, a biopharmaceutical firm headquartered in the U.S., for nearly USD 9 billion. Industry experts have stated that the former has entered a deal with the latter with an aim to gain a competitive edge in the cancer treatment sector. It has been anticipated that with the acquisition, the U.S. based biotechnology firm will gain a detailed insight into the cancer research therapies including CAR-T that utilizes the human’s own immune system to combat cancer tumors.

As per the terms & conditions of the pact, Celgene will have to pay USD 87 per share in cash to Juno, which is 91% more than the latter’s share price last displayed on the stock market January 16th, the day before Wall Street Journal stated the ongoing discussions between the firms related to the agreement. It has been known that the New Jersey based biotech company was increasing its research work on the creation of new drugs for treating cancer after its high revenue generating blood cancer medicine, Revlimid, failed the Phase II clinical trials conducted last month.

Reports have confirmed that both the firms have been associated with each other since 2015 for developing new therapies for treating cancer with Juno being the largest investor. Apparently, after the announcement of the deal Juno’s share price increased by 27% at USD 86.20, while the Celgene’s share price at USD 102.55 demonstrated a minimal change.

Industry professionals believe that the Celgene’s acquisition of Impact Biomedicines Inc.  followed by its purchase of Juno is a part of its business strategy to recover the revenue loss it had incurred due to the failed clinical tests for its best-selling blood cancer drug Revlimid. Furthermore, sources have stated that the acquisition agreement between both the firms is likely to be finalized in the first quarter of 2018. 



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Global CAD for VARs Market Outlook Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023
Author: Partha Ray

New report of Global CAD for VARs Market Report communicates about the manufacturing process. The process is analyzed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs and the a...


CAD Market Global Briefing and Future Outlook 2018 to 2023
Author: Partha Ray

Market Study Report add Global CAD market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the lea...


Cable Tray Market by Technology, Application & Geography Analysis & Forecast to 2023
Author: Partha Ray

Market Study Report Add New Global Cable Tray Market Report to its research database. The report presents a deep study of the market growth factors and drivers, application potential and much more.

Cable trays are a safe and feasible sol...